The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI).
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Jinju Li
No Relationships to Disclose
 
Jonathan Chou
Stock and Other Ownership Interests - Array BioPharma (I); Atara Biotherapeutics (I); Bluebird Bio (I); Celgene (I); Exelixis (I)
Research Funding - Amgen Astellas BioPharma (Inst)
 
Melissa Andrea Reimers
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Pfizer (Inst); FORMA Therapeutics (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Clovis Oncology; Merck; Sanofi; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Myovant Sciences; Seagen
Speakers' Bureau - AstraZeneca; Merck Sharp & Dohme; Sanofi; Seagen; Seagen
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Bayer
 
Stephanie Daignault-Newton
Other Relationship - American Urological Association
 
Phillip Lee Palmbos
Research Funding - Immunomedics; Roche
 
Zachery R Reichert
Consulting or Advisory Role - Dendreon
Research Funding - AstraZeneca (Inst)
 
Marcin Cieslik
No Relationships to Disclose
 
Arul Chinnaiyan
Stock and Other Ownership Interests - Esanik; LynxDx; Oncopia Therapeutics; Tempus
Honoraria - BMS
Consulting or Advisory Role - Ascentage Pharma; EdenRoc Sciences; Esanik; LynxDX; Oncopia Therapeutics; Rappta Therapeutics; Tempus
Patents, Royalties, Other Intellectual Property - University of Michigan Patents
 
Wassim Abida
Honoraria - Aptitude Health; Clinical Education Alliance; Medscape; OncLive/MJH Life Sciences; Roche
Consulting or Advisory Role - Clovis Oncology; Daiichi Sankyo; Janssen; ORIC Pharmaceuticals
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Epizyme (Inst); ORIC Pharmaceuticals (Inst); Zenith Epigenetics (Inst)